Novartis Earnings Per Share vs. Market Capitalization

NVS Stock  USD 98.35  1.07  1.10%   
Based on Novartis' profitability indicators, Novartis' profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Novartis' ability to earn profits and add value for shareholders. At this time, Novartis' Days Sales Outstanding is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.37 in 2024, whereas EV To Sales is likely to drop 2.82 in 2024. At this time, Novartis' Net Income Per E B T is comparatively stable compared to the past year.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.780.7327
Notably Up
Slightly volatile
Net Profit Margin0.170.3183
Way Down
Pretty Stable
Operating Profit Margin0.180.2094
Fairly Down
Pretty Stable
Pretax Profit Margin0.250.1955
Significantly Up
Pretty Stable
Return On Assets0.110.1486
Way Down
Pretty Stable
Return On Equity0.330.3182
Sufficiently Up
Slightly volatile
For Novartis profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Novartis to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Novartis AG ADR utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Novartis's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Novartis AG ADR over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.215
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
23.168
Quarterly Revenue Growth
0.097
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Novartis AG ADR Market Capitalization vs. Earnings Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth.
Novartis AG ADR is regarded fourth in earnings per share category among related companies. It is rated below average in market capitalization category among related companies creating about  48,524,213,073  of Market Capitalization per Earnings Per Share. At this time, Novartis' Market Cap is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Novartis by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novartis' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novartis' earnings, one of the primary drivers of an investment's value.

Novartis Market Capitalization vs. Earnings Per Share

Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Novartis

Earnings per Share

 = 

Earnings

Average Shares

 = 
4.10 X
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Novartis

Market Cap

 = 

Shares Outstanding

X

Share Price

 = 
198.95 B
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Novartis Market Capitalization vs Competition

Novartis AG ADR is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is now estimated at about 2.95 Trillion. Novartis holds roughly 198.95 Billion in market capitalization claiming about 7% of equities under Health Care industry.
Capitalization  Valuation  Revenue  Total debt  Workforce

Novartis Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Novartis, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Novartis will eventually generate negative long term returns. The profitability progress is the general direction of Novartis' change in net profit over the period of time. It can combine multiple indicators of Novartis, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income45.9 B52.6 B
Operating Income9.8 B9.9 B
Income Before Tax9.1 B10.2 B
Total Other Income Expense Net-227 M-215.7 M
Net Income8.6 B8.8 B
Income Tax Expense551 M523.5 M
Net Income Applicable To Common SharesB9.8 B
Net Income From Continuing Ops8.2 B10.8 B
Interest Income627 M595.6 M
Net Interest Income-492 M-516.6 M
Change To Netincome3.3 B3.5 B
Net Income Per Share 7.15  7.51 
Income Quality 1.69  1.10 
Net Income Per E B T 1.63  1.71 

Novartis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Novartis. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Novartis position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Novartis' important profitability drivers and their relationship over time.

Use Novartis in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novartis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novartis will appreciate offsetting losses from the drop in the long position's value.

Novartis Pair Trading

Novartis AG ADR Pair Trading Analysis

The ability to find closely correlated positions to Novartis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novartis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novartis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novartis AG ADR to buy it.
The correlation of Novartis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novartis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novartis AG ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novartis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Novartis position

In addition to having Novartis in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Office Supplies Thematic Idea Now

Office Supplies
Office Supplies Theme
Companies producing and selling office supplies, and accessories. The Office Supplies theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Office Supplies Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out Correlation Analysis.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
To fully project Novartis' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Novartis AG ADR at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Novartis' income statement, its balance sheet, and the statement of cash flows.
Potential Novartis investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Novartis investors may work on each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.